Skip to main content
Clinical Trials/NCT02100202
NCT02100202
Unknown
Not Applicable

Efficacy and Safety Study of Dietary Supplements (BioTurmin, BioTurmin-WD and MaQxan) on Cotinine Level and Oxidative Stress Marker in Chronic Smokers Having Mild to Moderate Hyperlipidemia

Olive Lifesciences Pvt Ltd1 site in 1 country60 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Smokers
Sponsor
Olive Lifesciences Pvt Ltd
Enrollment
60
Locations
1
Primary Endpoint
Change in urine cotinine and serum oxidative stress marker levels
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate hyperlipidemia after 30 days of intervention.

Detailed Description

In a randomized, double-blind, placebo control trial, the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) will be investigated in chronic smokers having mild to moderate hyperlipidemia. Sixty subjects will be randomly assigned to receive the dietary supplements and placebo for 30 days. The efficacy of the supplements will be measured by estimating cotinine and malondialdehyde level.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
July 2014
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
Olive Lifesciences Pvt Ltd
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Men \> 20 years
  • Chronic cigarette/ beedi smoker (2-3 packets/day since last 3 years or more) with mild to moderate hyperlipidemia (LDL ranging 160-189 mg/dL, TC \>200 mg/dL and/or HDL-C \<40 mg/dL)
  • Being mentally competent and able to understand all study requirements and sign the informed consent form.

Exclusion Criteria

  • Patients with Chronic obstructive pulmonary disease (COPD)
  • Patients with severe liver, renal, cardiac or brain diseases.
  • Unable to complete follow up.
  • Subjects on any medication like diuretics.
  • Allergic to any medication.
  • With a history of alcohol and/or drug abuse.

Outcomes

Primary Outcomes

Change in urine cotinine and serum oxidative stress marker levels

Time Frame: Baseline and on day 30

nicotine metabolite (cotinine) and serum oxidative stress marker (malondialdehyde) levels

Secondary Outcomes

  • Change in serum lipid profile(Baseline and on day 30)

Study Sites (1)

Loading locations...

Similar Trials